Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-599 (Elsubrutinib + Upadacitinib) in RA
NCT03682705Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of elsubrutinib in rheumatoid arthritis (RA) (6 arms), sponsored by AbbVie Inc. Primary endpoint: Disease Activity Score 28 C-reactive Protein at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
elsubrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03682705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682705.